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Abstract: The absence of herd immunity to orthopoxviruses and the concern that variola or 
monkeypox  viruses  could  be  used  for  bioterroristic  activities  has  stimulated  the 
development of therapeutics and safer prophylactics. One major limitation in this process is 
the lack of accessible human orthopoxvirus infections for clinical efficacy trials; however, 
drug licensure can be based on orthopoxvirus animal challenge models as described in the 
“Animal Efficacy Rule”. One such challenge model uses ectromelia virus, an orthopoxvirus, 
whose natural host is the mouse and is the etiological agent of mousepox. The genetic 
similarity of ectromelia virus to variola and monkeypox viruses, the common features of the 
resulting disease, and the convenience of the mouse as a laboratory animal underscores its 
utility in the study of orthopoxvirus pathogenesis and in the development of therapeutics 
and prophylactics. In this review we outline how mousepox has been used as a model for 
smallpox. We also discuss mousepox in the context of mouse strain, route of infection, 
infectious dose, disease progression, and recovery from infection. 
Keywords:  ectromelia;  variola;  monkeypox;  animal  model;  mousepox;  infection  route; 
antiviral; CMX001; ST-246 
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1. Ectromelia virus 
Infectious ectromelia (ECTV) was identified in 1930 when the mouse was first introduced as an 
experimental laboratory animal [1]. Wild populations of rodents in Europe are suspected to be infected 
naturally with ECTV and the virus is transmitted easily among wild and laboratory populations under 
experimental conditions [2]. Mice that survive the acute phase of disease develop an exanthematous 
rash called mousepox that is similar to that of smallpox. ECTV causes an acute epizootic disease in 
mouse colonies in Europe, Japan, China and the US [3-5]. Laboratory studies have shown that ECTV, 
like Variola virus (VARV) infections in humans, has a very narrow host range, infecting only certain 
mouse species [6]. The genetic similarities of VARV and ECTV, and the commonality of disease 
course led to ECTV being proposed as a model of smallpox and exanthematous diseases in the 1940s. 
In this capacity, mousepox provides an excellent model for testing anti-orthopoxvirus therapeutics and 
prophylactics [7-8]. This rudimentary understanding of ECTV infection of the mouse and spread to 
internal organs during the disease incubation period still forms the conceptual basis for the incubation 
period of smallpox and human monkeypox. Studies from a succession of investigators in the last five 
decades  have  resulted  in  a  detailed  description  of  the  virologic  and  pathologic  disease  course  in 
genetically susceptible (A, BALB/c, DBA/2, and C3H/He) and resistant (C57BL/6, SKH1 and AKR) 
inbred and outbred mice; identification and characterization of important cell-mediated and innate 
responses for recovery from infection [9-19]; and the discovery of rmp-1, rmp-2, rmp-3 and rmp-4 loci 
which govern resistance to severe mousepox [20-23]. Varying mouse genotypes, virus strain and dose 
of virus result in distinct disease patterns for a given route of infection.  
Mousepox as a model of smallpox 
Mousepox has at least four features similar to smallpox (Figure 1). First, a relatively small dose of 
virus is required to initiate disease in the upper and lower respiratory tract (although the actual dose 
required to initiate smallpox is unknown, it is generally accepted to be a low dose [24]). Second, 
following a low dose intranasal (IN) infection there is no obvious lung involvement during the course 
of early disease (data not shown). Third, virus can be detected in respiratory gases during the pre-
exanthem period [25]. And fourth, both diseases present with a characteristic exanthematous rash, 
although in the case of mousepox, rash development is dependent on a number of parameters including 
mouse strain, virus strain, route of inoculation, and virus dose [3]. Mousepox differs from smallpox in 
at least two features following respiratory tract infection. First, the disease course in mousepox is 
shorter as compared to smallpox. Death in fatal cases of mousepox usually occur 7 to 14 days p.i., 
whereas deaths in ordinary smallpox occur approximately 18 to 22 days p.i. [24]. Second, the major 
lesions  in  mousepox  are  observed  in  the  liver  and  spleen,  whereas  these  organs  are  relatively 
uninvolved in smallpox [4,24].  
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Figure 1. The spread of virus around the body and the evolution and healing of skin 
lesions in the mousepox system and in smallpox in humans (courtesy of the WHO [24]). 
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2. The animal efficacy rule 
Naturally occurring smallpox was eradicated in the late 1970s by a global vaccination program 
sponsored by the WHO. Human monkeypox, although on the rise, is still sporadic and usually occurs 
in  the  tropical  rain-forests  of  Africa  [26].  Therefore,  there  are  insufficient  numbers  of  accessible 
human orthopoxvirus infections for clinical efficacy trials. In recognition of this problem, the Food and 
Drug Administration (FDA) promulgated the so-called “Animal Efficacy Rule”, which acknowledges 
that  therapeutics  and  prophylactics  against  NIAID  (National  Institute  of  Allergy  and  Infectious 
Diseases)  Category  A  biothreat  agents  cannot  be  licensed  under  the  usual  regulatory  standards  
(21 CFR 314 or 601). (United States Code of Federal Regulations title 21, part 314, subpart I, Federal 
Register, 2002). The Animal Efficacy Rule permits the use of well-controlled animal efficacy data to 
support an application for licensure of drugs and biological products intended to treat, or prevent, 
serious  or  life-threatening  conditions  in  humans  resulting  from  exposure  to  biological,  chemical, 
radiological  or  nuclear  substances.  Product  Licensure  requires  that  the  Animal  Efficacy  Rule  be 
utilized if human challenge or protection efficacy trials to test the product would be unethical due to 
the risks associated with exposure, or when clinical field trials are unfeasible (e.g. VARV no longer 
circulates in human populations). Although the selection of animal models is left up to the scientific 
judgment of the principal investigator, a typical choice would involve at least one rodent and non-
human primate model.  
The  Animal  Efficacy  Rule  presents  regulatory  hurdles  for  licensure  of  vaccines  and  poxvirus 
antivirals [27-28]. The criteria for animal data use in licensure of products under the Animal Efficacy 
Rule is stated in Table 1, and is matched to the realities of smallpox product development in animal 
models [28]. The first three sections of Table 1 apply equally to vaccines and antivirals with the fourth 
section specifically addressing issues relevant with antivirals. Although the available animal models 
can be characterized in great detail using modern molecular and immunologic techniques, little is 
known  about  the  molecular  and  cellular  basis  of  the  pathogenesis  of  VARV  or  monkeypox  virus 
(MPXV),  especially  during  the  10-12  day  incubation  period  that  was  modeled  on  a  1950s 
understanding  of  mousepox.  There  is  no  single  animal  model  that  mimics  smallpox  and  human 
monkeypox accurately. The animal models differ from human disease in the infectious dose required 
to initiate infection, tissues targeted for pathology, and duration of disease. The licensure of smallpox 
antivirals requires a profound and sustained research effort, and constant open dialog among the drug 
sponsor,  regulatory  authorities  and  government  agencies  to  reduce  the  Animal  Efficacy  Rule  to 
practice [28]. 
In the case of antiviral development, the sole use of animal efficacy data as a means of establishing 
an effective human dose is problematic [28]. Because there are no pharmacodynamic responses in 
animal  models  that  can  predict  the  human  response  to  an  anti-orthopoxvirus  drug,  human  dose 
selection must be based on kinetics. For example, the hexadecyloxypropyl lipid side chain of CMX001 
is subject to oxidative catabolism in mice, rats, rabbits, monkeys, and humans. However the extent of 
the catabolism, and the precise intermediates along the catabolic pathway isolated from plasma vary 
significantly between species. This results in very different plasma exposures in animals of different 
species given the same mg/kg dose. Consequently it is difficult, if not impossible, to calculate directly 
an efficacious dose in a given species based on the efficacious dose determined experimentally in Viruses 2010, 2                         
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another. However, it is possible to scale efficacious plasma exposure directly between species using 
the pharmacokinetic parameters of Cmax and AUC o⇒∞. In mice, for example, an efficacious dose of 
CMX001 against an ECTV infection is 5 mg/kg. This dose results in a plasma exposure to CMX001 
with a Cmax of 29 ng/ml and an AUC o⇒∞ of 60 ng/ml/hr. In order to achieve this plasma exposure in 
humans requires a significantly lower dose of 1 mg/kg. This difference is largely due to differences in 
degree of oxidative catabolism between mice and humans. It is noteworthy that this dose in humans 
has  shown  a  clinical  efficacy  against  vaccinia  virus  (VACV),  adenovirus  and  cytomegalovirus 
infections, supporting the idea that activity against ECTV in mice can be used to help establish an 
efficacious human dose against relevant orthopoxviruses as well as other double stranded DNA virus 
infections. 
Table 1. Elements of the animal efficacy rule
1. 
Criteria for use of animal model  Issues relating to smallpox 
There  is  reasonably  well  understood 
pathophysiological  mechanism  for  the 
toxicity  of  the  substance  and  its 
prevention or substantial reduction by the 
product. 
•  Scientific knowledge is limited as the last cases of 
endemic smallpox occurred in 1949 in the USA, and 
1977  worldwide,  prior  to  the  age  of  molecular 
biology and immunology. 
The  effect  is  demonstrated  in  more 
than one animal species expected to react 
with  a  response  predictive  for  humans, 
unless  the  effect  is  demonstrated  in  a 
single  animal  species  that  represents  a 
sufficiently  well  characterized  animal 
model for predicting human response. 
•  VARV naturally infects only humans; experimental 
infection of nonhuman primates is forced. 
•  Animal  models  using  related  orthopoxviruses 
produce  disease  with  similarities  to  smallpox,  but 
the  pathogenesis  varies  depending  on  the  animal 
species, the characteristics of the infecting virus and 
the route of infection. 
•  No  one  animal  model  has  been  established  that 
completely mimics human disease. 
The  animal  study  endpoint  is  related 
clearly to the desired benefit in humans, 
generally the enhancement of survival or 
prevention of major morbidity. 
•  There  are  no  animal  models  for  the  major 
morbidities of smallpox. 
•  Orthopoxvirus  doses  sufficient  to  produce  100% 
mortality  in  animal  models  shorten  the  incubation 
period  substantially  in  most  animal  models,  thus 
making  it  difficult  to  study  the  effect  of  post-
exposure intervention. 
•  Interpretation  of  mortality  studies  in  animals  are 
limited  by  the  ethical  requirement  to  euthanize 
moribund animals. 
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Table 1. Cont. 
Criteria for use of animal model  Issues relating to smallpox 
The  data  or  information  on  the 
pharmacokinetics and pharmacodynamics 
of  the  product  or  other  relevant  data  or 
information,  in  animals  and  humans, 
allow  selection  of  an  effective  human 
dose. 
•  The specific pharmacodynamic response related to 
antipoxviral a c t i v i t y  c a n n o t  b e  m e a s u r e d  i n  
uninfected humans for the purpose of selecting an 
effective dose. 
•  Pharmacokinetics  in  the  animal  species  used  in 
orthopoxvirus infection models may not be the most 
relevant for dose selection in humans. 
1 Adapted from Future Virology (2006) 1(2) 173-179 with permission of Future Medicine Ltd [28]. 
 
3. Mousepox severity is dependent on mouse strain 
We and others have previously shown that a very low dose of ECTV virus (<10 Plaque forming 
units, PFU) delivered by the footpad (FP) and subcutaneous (SC) routes induces uniform mortality in 
A/Ncr mice by day 8 p.i. [29-30]. Conversely, infections of the C57BL/6 and SKH-1 strains via the 
SC/FP routes result in a milder, non-lethal illness with high LD50 (lethal dose 50%) values of >1 x 10
6 
PFU and >2000 PFU, respectively [31]. Interestingly, the response to a FP infection in the C57BL/6 
strain is so strong that it can protect IN infected mice from lethal infections when administered at least 
24 hours after the IN infection (data not shown and [29]).  
The  vastly  different  disease  outcomes  following  FP/SC  infections  have  been  most  thoroughly 
studied in the C57BL/6 and A/Ncr strains. Following a 100 PFU FP infection in the A/Ncr strain, 
infectious virus can be detected in the spleen by 2 days p.i., in the liver by 4 days p.i. and in the lungs 
by 6 days p.i.; however, in the C57BL/6 strain very low levels of infectious virus are detected in the 
liver at day 5 p.i. but none is detected in the spleen or lung. Conversely, when the A/Ncr and C57BL/6 
strains are infected IN with 1000 PFU, 100% mortality is observed by day 8 p.i. and day 14 p.i. 
respectively. And, infectious virus can be detected from day 2 and day 4 p.i. in the liver, spleen and 
lung of A/Ncr and C57BL/6 mice, respectively; however, viral titers are consistently 1-2 logs lower in 
C57BL/6 mice compared to equivalent tissues from A/Ncr mice [29].  
Some insights into the reason for the different disease outcomes following FP infections can be 
gleaned by examining the draining popliteal lymph nodes (PLN) of the C57BL/6 and A/Ncr strains. 
We found that there was minimal overlap in the host gene transcription pattern between the C57BL/6 
and A/Ncr PLNs at 6, 12 and 24 hours p.i. (data not shown). Also, several cytokines, such as IFNγ and 
Rantes, were elevated in C57BL/6 PLN cells by 24-48 hours p.i. but were only slightly elevated or 
unchanged in A/Ncr PLN cells, respectively [29]. Furthermore, PLN cells from C57BL/6 mice present 
antigen to pre-primed CD3+ splenocytes by 24 hours p.i.; however, no such presentation could be 
detected in the equivalent experiment using A/Ncr mice up to 72 hours p.i. [29]. That said, the A/Ncr 
PLN was not completely unresponsive because IL-9 levels were elevated by 24 hours p.i. but remained 
unchanged in the PLN of the C57BL/6 strain [29]. These cytokine response differences could indicate 
a Th1 and Th2 biased response in the C57BL/6 and A/Ncr strains, respectively. Thus, following a FP Viruses 2010, 2                         
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infection  the  protective  innate/adaptive  immune  response  is  initiated  earlier,  and  is  qualitatively 
different, in the C57BL/6 mouse strain as compared to the A/Ncr strain. 
4. Importance of route and infectious dose in animal models of smallpox 
4.1. Route of infection 
The pathogenesis of an infectious agent is greatly affected by its route of infection. VARV causes a 
systemic, fulminant disease following a respiratory tract infection with a case-fatality rate of 10-30%. 
Epidemiologic studies suggested that this infection is mediated by large-droplet aerosol that would 
initiate infection in the upper respiratory tract, which is modelled by the IN route of infection. In 
contrast, infection through the skin results in a systemic infection, but with a milder disease course and 
case-fatality rate of <1% [24]. Therefore, it is important that the route of infection and the challenge 
virus  used  to  evaluate  antivirals  recapitulate  the  pathogenesis  of  the  natural  disease  and  the  host 
response to it. Certain rabbit/rabbitpox virus and monkey/monkeypox virus models utilize intradermal 
and intravenous (IV) routes of infection, respectively, that remove the seeding and early stages of viral 
replication in the respiratory tract [32-34].  
The  A/Ncr  strain  is  sensitive  to  lethal  ECTV  infection  by  IV,  IN,  FP/SC  and  IP  routes.  The 
C57BL/6 mouse is resistant to FP/SC ECTV infections but is highly sensitive to IV (LD50 = 10,000) 
and IN (LD50 = 100 PFU) infections [31]. The IV route has also been evaluated in the ECTV model but 
has some distinct disadvantages compared to the natural route of VARV transmission. Primarily, the 
instantaneous viremia shortens the incubation and prodromal phases of the disease. Thus, the battery of 
ECTV encoded evasion molecules that dampen the innate response to infection in the skin are likely 
compromised  or  completely  bypassed.  It  has  also  been  shown  that  the  virus  inoculum  is  rapidly 
inactivated  by  complement,  which  thereby  reduces  the  viral  challenge  dose  and  likely  facilitates 
accelerated antigen presentation. In our hands, we observed six-fold increases in blood CD8+ T cells 
secreting IFN-γ following IV infections as compared to the IN route (data not shown). Moreover, one 
report reveals that following an IV challenge the liver clears 95% of ECTV from circulation within 
five  minutes  of  injection.  In  the  following  hour,  most  of  the  viral  antigen  in  the  liver  becomes 
undetectable  by  immunefluorescence  and  viral  infectivity  decreases  by  90%.  Such  rapid  removal 
further supports the hypothesis that the virus has been recognized and tagged for immune adherence 
and destruction [35-36].  
The  importance  of  infectious  route  has  been  studied  in  the  C57BL/6  mouse  following  an  IN 
infection or a SC infection in the nose. Rapid changes are observed in the transcriptional pattern of 
cells isolated from the mandibular lymph node (MLN) which drains both sites of infection (Figure 2). 
Arrival of the virus at the MLN following a SC infection occurs at 12 hours p.i. as measured by 
infectivity  titers  and  GFP+  cells,  but  is  delayed  until  day  3-4  p.i.  (measured  by  GFP+  cells)  and  
day 1-2 p.i. (measured with titers) following IN inoculation (data not shown). As well as arriving at the 
MLN earlier, a SC infection results in the arrival of the virus at the spleen, liver, kidney and lung 
approximately 2 days earlier than it does following an IN infection; however, titers remain 1-3 logs 
lower  in  tissues  from  a  SC  infection  compared  to  those  from  an  IN  infection.  Furthermore,  the 
cytokine profiles in the plasma and at the MLN are different for each route. For example, C57BL/6 Viruses 2010, 2                         
 
 
1925 
mice infected via the SC route have detectable plasma IFNγ by day 1 p.i. which peaks at day 4 p.i. 
followed by a rapid reduction in levels by day 6 p.i. In contrast, following an IN infection, plasma 
IFNγ cannot be detected until day 3 p.i. but is followed by a rapid increase which continues until death. 
At  the  MLN,  IFNγ,  IL-6,  KC  (keratinocyte  chemoattractant,  CXCL1),  and  MCP-1  (monocyte 
chemoattractant protein-1, CCL2) are increased following a SC infection, but remain at control levels 
following an IN infection; Rantes (regulated upon activation normal T cell expressed and secreted, 
CCL5), however, is increased significantly at day 6 and day 7 in mice infected by the SC and IN routes 
[31]. The dramatic route-dependent differences in the host response to infection argues that animal 
models of smallpox should use the same infection route. 
Figure 2. Gene chip arrays were used to measure up-regulated and down-regulated genes 
in the MLN of C57BL/6 mice infected IN or SC with ECTV at 12 hours, day 1 and day  
2 p.i. 
 
 
4.2. Infectious Dose 
Based on several lines of evidence, the infectious dose of VARV is likely very low  [26]. For 
example, infectivity was detected in oropharygeal secretions of infectious smallpox patients between 
two and nine days from onset of fever, and titers rarely were >10
5 PFU/ml [24]. The virus was virtually 
undetectable in the air of smallpox wards unless measured within a short distance of the patients mouth 
[37-38].  Also,  epidemiologic  studies  of  the  Aralesk,  Meschede,  and  University  of  Birmingham Viruses 2010, 2                         
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smallpox outbreaks support a low infectious dose [24,39]. And finally, experimental studies with other 
orthopoxviruses have initiated infections with small doses of virus: 4 PFU of VACV (Westin Reserve 
strain) in rabbits, 15 PFU of rabbitpox (Utrecht Strain) in rabbits and 0.6 PFU of ECTV in mice 
[33,40]. Based on this data, animal models of smallpox should employ relative low challenge doses.  
5. Indicators of disease progression and recovery from infection 
5.1. Disease progression 
Disease  biomarkers  provide  a  good  method  to  monitor  disease  progression  and  the  efficacy  of 
antiviral therapies. Biomarkers have been most thoroughly studied in the A/Ncr and C57BL/6 mice 
following  an  IN  infection  and  include:  1)  AST  (alanine  aminotransferase)  and  ALT  (aspartate 
aminotransferase)  which  give  an  indication  of  liver  damage;  2)  ECTV  DNA  can  be  detected  and 
quantified with PCR (polymerase chain reaction) from whole blood as early as 4 days p.i.; and 3) 
Weight change provides a good trailing indicator of morbidity (see Table 2) [40]. Monitoring of core 
body temperature by telemetry has not provided a robust measure of disease progress work [31].  
5.2. Recovery from infection 
Recovery from IN infection is easily monitored by observing increases in animal body weight and 
by  measuring:  1)  blood  neutrophilia;  2)  serum  IFN-γ;  3)  ALT/AST;  4)  infectivity  titres;  5)  DNA 
genome equivalents; and 6) levels of circulating IFN-γ secreting CD4 and CD8 T cells (Table 2). 
Importantly  all  of  these  measurements  can  be  made  from  100  µl  of  blood  obtained  from  the 
submandibular  vein  without  the  need  to  sacrifice  the  animal  [40].  To  determine  if  the  antiviral 
treatment has an effect on development of immunity to ECTV, we also monitor the antibody and cell-
mediated memory responses at ~60 days p.i., and the ability of the surviving antiviral-treated mice to 
resist a second ECTV challenge (~1000x LD50). 
6. Selecting a trigger for therapeutic intervention  
Although  various  biomarkers  have  been  evaluated  to  stage  disease  progression,  the  trigger  for 
intervention has not been linked to an outwardly observable clinical sign of disease. The use of a 
“disease-defining manifestation” relevant to human disease to initiate therapy in an animal model is 
important for the generation of efficacy data under the Animal Rule as described in a 2009 FDA 
guidance document [41]. In an animal model of smallpox/human monkeypox the appearance of rash 
would be an ideal trigger as it appears 10-12 days following infection and contributes to clinical 
differential diagnosis. Observation of rash in C57BL/6 mice is difficult to visualise due to the presence 
of hair, although waxing the mice at various stages p.i. can been used to more easily see a rash-like 
pathology  which  presents  itself  from  approximately  day  7-14  p.i.,  depending  on  challenge  dose. 
Another  strain  that  has  been  used  to  evaluate  antivirals  is  the  hairless  SKH1  strain.  SKH1  mice 
respond to ECTV infection in a strikingly similar way to that of the C57BL/6 strain, i.e., the mice are 
resistant to FP/SC infections but are sensitive to IN infections (LD50 = 100 PFU). Furthermore, the 
manifestation of the rash in the SKH1 strain is much more obvious and wide-spread compared to the 
rash-like pathology in the C57BL/6 strain which can present with as few as 10 lesions. Preliminary Viruses 2010, 2                         
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data indicate that rash appearance in these mouse strains occurs too late in disease to be used as a 
trigger for therapeutic intervention with an antiviral [31]. 
Table 2. Indicators of disease progression and host response in A/Ncr and C57BL/6 mice 
infected with ECTV via the IN, SC or FP route
1. 
Marker  Route  A/Ncr  C57BL/6 
Disease Progression 
IN  7-8 (1000 PFU); 7-12 (20 PFU)  9-14 (1000 PFU); 
Day of death 
FP  7-8 (1000 PFU)  N/A 
IN  Lose  weight  from  day  5  (5-
1000 PFU  Lose weight from day 7 (1000 PFU) 
Weight change 
FP  Lose weight from day 5 (1000 
PFU) 
N/A 
IN  Day  2  spleen,  liver  and  lung 
(1000 PFU) 
Day  3  liver;  day  4  spleen  and  lung 
(1000 PFU) 
Infectivity titres 
FP  Day 2 spleen; day 4 liver; and 
day 6 lung (1000 PFU) 
N/A 
ALT/AST  IN  Day 6 (1500 PFU)  >Day  7  (1500  PFU);  day  5  (1x10
6 
PFU) 
IN  Day 6 (5 PFU)  Day 4 (6500 PFU) 
Blood viral DNA 
FP  Day 5 (1000 PFU)  - 
       
Host Response 
IN  Day 4 (20 PFU)  Day 4 (1x10
6 PFU) 
IFN-γ 
SC  -  Day 2 (1x10
6 PFU) 
Neutrophilia  IN  By day 8 (20 PFU)  By day 6 (1x10
6 PFU) 
PLN IFN-γ  FP  Day 2 (1000 PFU)  Day 1 (1000 PFU) 
PLN Rantes  FP  No change (1000 PFU)  Day 1 (1000 PFU) 
PLN IL-9  FP  Day 1 (1000 PFU)  No change (1000 PFU) 
PLN  gene 
regulation 
FP  22  gene  changes  from  6-24 
hours p.i. (1000 PFU) 
80 gene changes from 6-24 hours p.i. 
(1000 PFU) 
IN  MLN no presentation up to day 
3 (1x10
6 PFU) 
MLN  no  presentation  up  to  day  3 
(1x10
6 PFU)  Antigen 
presentation 
FP  PLN no presentation up to day 
3 (1x10
6 PFU) 
PLN presentation from day 1 (1x10
6 
PFU) 
IN  No change  Doubled from day 4-7 
Spleen mass 
FP  No change  Trebled from day 4-7 
CD4  splenic 
intracellular  IFN-
γ 
FP 
2x10
5 IFN- γ + cells by day 8 
(3000  PFU  attenuated  virus 
EV-138) 
5x10
4 IFN- γ + cells by day 6 (3000 
PFU attenuated virus EV-138) 
CD8  splenic 
intracellular  IFN-
γ 
FP 
2.5x10
5 IFN- γ + cells by day 8 
(3000  PFU  attenuated  virus 
EV-138) 
2.5x10
6 IFN-γ+ cells by day 6 (3000 
PFU attenuated virus EV-138) 
Antibody  FP  N/A (1000 PFU)  Seroconversion by day 21 
1 Data taken from [29,31,40,42]. Viruses 2010, 2                         
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7. Evaluation of prophylactics and therapeutics in the ectromelia model 
7.1. Efficacy testing in ECTV infected immunocompetent mice 
The majority of recent efficacy studies have been performed in the A/Ncr, C56BL/6 and SKH1 
strains. Although the A/Ncr strain’s sensitivity to SC infections, and its general hyper-sensitivity to 
ECTV, does not model VARV/MPXV infections in humans, it does provide a platform for the testing 
of drugs in mice infected with viral doses several thousand times higher than the LD50. We and others 
have used the A/Ncr strain to evaluate two promising orally bioavailable antivirals that have different 
antiviral modes of inhibiting orthopoxviruses; namely, ST-246 and CMX001 [42-43]. We found that 
following a 50 PFU IN infection, a daily 4 mg/kg dose of CMX001 initiated on the day of infection 
and continued for 5 days could protect all A/Ncr mice. With ST-246 we found that following a 3 PFU 
IN infection all A/Ncr mice were protected when dosed with a daily 100 mg/kg dose of ST-246 for 10 
days commencing on the day of infection. A delayed CMX001 dosing regimen was therapeutically 
effective as late as 3 and 6 days p.i. in SKH1 and C57BL/6 mice, respectively, and ST-246 was 
therapeutically effective at 6 days p.i. in C57BL/6 mice.  
7.2. Efficacy testing smallpox antivirals in immunodeficient animals 
Immunocompromised patients infected with orthopoxviruses are a challenge to treat therapeutically 
as  optimal  antiviral  efficacy  is  dependent  on  a  functioning  immune  system.  In  certain 
immunocompromised patients, monotherapy evolves into a combination therapy due to the lack of 
clinical response. For example, a child with eczema vaccinatum was treated sequentially with VIG, 
cidofovir  (CDV)  and  ST-246  prior  to  clinical  progress  and  recovery  [44].  Similarly,  a  case  of 
progressive vaccinia, a rare and often fatal adverse event to vaccination was treated sequentially with 
VIG,  ST-246,  Imiquimod,  and  CMX001  prior  to  clinical  progress  and  recovery  [45].  These  two 
clinical cases involving patients with varying degrees of immunodeficiency, and the available antiviral 
studies  using  immunodeficient  animal  hosts  suggest  that  more  research  is  needed  to  evaluate 
combination antiviral therapies against poxviruses [46-51]. This is particularly relevant as a significant 
portion of the population are immunocompromised [52].  
Nude and SCID mice, and mice treated with ionizing radiation or cytostatic drugs, have been used 
to evaluate the efficacy of smallpox antivirals in immunodeficient hosts. Another approach is to use an 
ECTV recombinant expressing IL-4 (ECTV-IL-4), which induces a profound immunocompromised 
state in all tested mouse strains whether genetically resistant or previously vaccinated with a smallpox 
vaccine [53]. The evaluation of CMX001 and ST-246 in this model found that standard monotherapy 
failed  to  protect  against  lethal  ECTV-IL-4  infections;  however,  the  prophylactic  combined 
administration  of  CDV  or  CMX001  and  ST-246  significantly  protected  against  lethal  IN  or  FP 
challenges  with  ECTV-IL-4,  as  did  combination  therapy  with  CDV  and  an  anti-IL-4  monoclonal 
antibody [31]. The advantage of this approach is that the host is an immunocompetent mouse strain 
that requires no ancillary treatments to induce immunosupression which is a consequence of global 
effects of virally produced IL-4 on the innate and adaptive immune system. Viruses 2010, 2                         
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